肝内胆管癌新辅助治疗的热点与进展

林志文; 刘红枝; 曾永毅; 林科灿

doi:10.3969/j.issn.1001-5256.2023.09.002

肝内胆管癌新辅助治疗的热点与进展

DOI: 10.3969/j.issn.1001-5256.2023.09.002

林志文^{1, 2},
刘红枝^{1, 2},
曾永毅^{1, 2, 3},
林科灿^{1, 2, 3, , ,}

1.
福建医科大学孟超肝胆医院肝胆外科，福州 350025
2.
福建省肝病科学研究中心，福州 350025
3.
福建医科大学附属第一医院肝胆外科，福州 350005

基金项目:

‍国家自然科学基金 (62275050);

国家重点研发计划资助项目 (2022YFC2407304);

福建省科技创新联合资金项目 (2019Y9108);

福建省卫健委中青年科研重大项目 (2021ZQNZD013)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：林志文、刘红枝负责撰写论文；曾永毅、林科灿负责修改论文；林科灿负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
林科灿， kclin2002@126.com （ORCID： 0009－0009－9932－7284）

计量
- 文章访问数: 489
- HTML全文浏览量: 148
- PDF下载量: 124
- 被引次数: 0
出版历程
- 收稿日期: 2023-07-06
- 出版日期: 2023-09-19

Hotspots and advances in neoadjuvant therapy for intrahepatic cholangiocarcinoma

Zhiwen LIN^{1, 2},
Hongzhi LIU^{1, 2},
Yongyi ZENG^{1, 2, 3},
Kecan LIN^{1, 2, 3
, ,
,}

1.
Department of Hepatobiliary Surgery，Mengchao Hepatobiliary Hospital of Fujian Medical University，Fuzhou 350025，China
2.
Liver Disease Research Center of Fujian Province，Fuzhou 350025，China
3.
Department of Hepatobiliary Surgery，The First Affiliated Hospital of Fujian Medical University，Fuzhou 350005，China

Research funding:

‍National Natural Science Foundation of China (62275050);

National Key Research and Development Program (2022YFC2407304);

Fujian Provincial Science and Technology Innovation Joint Fund Project (2019Y9108);

Young Scientific Research Project of Fujian Provincial Health Commission (2021ZQNZD013)

More Information

Corresponding author: LIN Kecan， kclin2002@126.com （ORCID： 0009－0009－9932－7284）

摘要

摘要: 肝内胆管癌是起源于肝内二级及以上胆管分支上皮细胞的恶性肿瘤，其发病率在全世界范围内呈明显上升趋势，由于其发病隐匿，早期临床症状不典型，侵袭性强，确诊时常处于进展期，预后较差，根治性手术是延长患者生存期的唯一治疗方法，但术后极易发生复发和转移，5年生存率低。新辅助治疗是指在手术前给予药物治疗或其他治疗方式，以减小肿瘤的大小、降低复发风险、提高手术切除的成功率或为手术提供更佳的局部控制。目前尚无标准化的新辅助治疗方案，其对预后的潜在作用也存在争议。本文就肝内胆管癌新辅助治疗的热点与进展进行综述。
- 胆管上皮癌 /
- 肿瘤辅助疗法 /
- 肝切除术
Abstract: Intrahepatic cholangiocarcinoma （ICC） is a malignant tumor that originates from the epithelial cells of the intrahepatic bile ducts， specifically the secondary and higher branches. The incidence rate of ICC tends to increase significantly worldwide. Due to its insidious onset， atypical clinical symptoms in the early stage， and strong invasiveness， it is often in the advanced stage at the time of diagnosis， which may result in poor prognosis. Radical surgery is the only treatment method to prolong the survival time of patients， but recurrence and metastasis frequently occur after surgery， leading to a low 5－year survival rate. Neoadjuvant therapy refers to the administration of drug treatment or other treatment modalities before surgery to reduce tumor size， lower the risk of recurrence， increase the success rate of surgical resection， or provide better local control for surgery. Currently， there is still no standardized regimens for neoadjuvant therapy， and its potential impact on prognosis remains controversial. This article reviews the hotspots and advances in neoadjuvant therapy for ICC.
- Cholangiocarcinoma /
- Neoadjuvant Therapy /
- Hepatectomy

HTML全文

参考文献(71)

[1]	SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72( 1): 7－ 33. DOI: 10.3322/caac.21708.
[2]	KOSHIOL J, YU BB, KABADI SM, et al. Epidemiologic patterns of biliary tract cancer in the United States: 2001－2015[J]. BMC Cancer, 2022, 22( 1): 1178. DOI: 10.1186/s12885－022－10286－z.
[3]	HU LS, ZHANG XF, WEISS M, et al. Recurrence patterns and timing courses following curative－intent resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2019, 26( 8): 2549－ 2557. DOI: 10.1245/s10434－019－07353－4.
[4]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009.
[5]	ERSTAD DJ, WITT RG, WARGO JA. Neoadjuvant therapy for melanoma: New and evolving concepts[J]. Clin Adv Hematol Oncol, 2022, 20( 1): 47－ 55.
[6]	SAAD M, TARHINI AA. Neoadjuvant therapy in melanoma: Where are we now?[J]. Curr Oncol Rep, 2023, 25( 4): 325－ 339. DOI: 10.1007/s11912－023－01369－6.
[7]	GUGENHEIM J, CROVETTO A, PETRUCCIANI N. Neoadjuvant therapy for pancreatic cancer[J]. Updates Surg, 2022, 74( 1): 35－ 42. DOI: 10.1007/s13304－021－01186－1.
[8]	QUEZADA－DIAZ FF, SMITH JJ. Neoadjuvant therapy for rectal cancer[J]. Surg Oncol Clin N Am, 2022, 31( 2): 279－ 291. DOI: 10.1016/j.soc.2021.11.008.
[9]	HARBECK N. Neoadjuvant and adjuvant treatment of patients with HER2－positive early breast cancer[J]. Breast, 2022, 62( Suppl 1): S12－S16. DOI: 10.1016/j.breast.2022.01.006.
[10]	NUVOLA G, RIZZO A, MOLLICA V, et al. The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?[J]. Immunotherapy, 2022, 14( 4): 171－ 174. DOI: 10.2217/imt－2021－0324.
[11]	ZOU JA, ZENG Y, WU F. Opportunities and challenges of neoadjuvant targeted therapy in nonsmall cell lung cancer[J]. Curr Opin Oncol, 2023, 35( 1): 22－ 30. DOI: 10.1097/CCO.0000000000000914.
[12]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20( 2): 163－ 170. DOI: 10.3760/cma.j.cn115610－20201211－00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20( 2): 163－ 170. DOI: 10.3760/cma.j.cn115610－20201211－00776.
[13]	XIAO ZY, CHEN YJ. Mode and option of neoadjuvant therapy for hepatobiliary neoplasms[J]. Chin J Pract Surg, 2023, 43( 3): 276－ 280. DOI: 10.19538/j.cjps.issn1005－2208.2023.03.06. 肖治宇, 陈亚进. 肝胆肿瘤新辅助治疗的模式及方案选择[J]. 中国实用外科杂志, 2023, 43( 3): 276－ 280. DOI: 10.19538/j.cjps.issn1005－2208.2023.03.06.
[14]	Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti－Cancer Association. Chinese expert consensus on conversion therapy in hepatocellular carcinoma(2021 edition)[J]. Chin J Pract Surg, 2021, 41( 6): 618－ 632. DOI: 10.19538/j.cjps.issn1005－2208.2021.06.02. 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41( 6): 618－ 632. DOI: 10.19538/j.cjps.issn1005－2208.2021.06.02.
[15]	HUANG LL, XIA Y, SHEN F. Difficulties and strategies of neoadjuvant therapy for intrahepatic cholangiocarcinoma[J]. Chin J Pract Surg, 2023, 43( 3): 291－ 298. DOI: 10.19538/j.cjps.issn1005－2208.2023.03.09. 黄莉莉, 夏勇, 沈锋. 肝内胆管癌新辅助治疗难点及策略[J]. 中国实用外科杂志, 2023, 43( 3): 291－ 298. DOI: 10.19538/j.cjps.issn1005－2208.2023.03.09.
[16]	BENSON AB, D’ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19( 5): 541－ 565. DOI: 10.6004/jnccn.2021.0022.
[17]	Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group. Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476. 中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476.
[18]	MASON MC, MASSARWEH NN, TZENG CW D, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience[J]. Ann Surg Oncol, 2021, 28( 11): 6725－ 6735. DOI: 10.1245/s10434－020－09536－w.
[19]	YADAV S, XIE H, BIN－RIAZ I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis[J]. Eur J Surg Oncol, 2019, 45( 8): 1432－ 1438. DOI: 10.1016/j.ejso.2019.03.023.
[20]	BUETTNER S, KOERKAMP BG, EJAZ A, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients－A multi－institutional analysis[J]. J Surg Oncol, 2017, 115( 3): 312－ 318. DOI: 10.1002/jso.24524.
[21]	KATO A, SHIMIZU H, OHTSUKA M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: A retrospective single－center study[J]. Ann Surg Oncol, 2013, 20( 1): 318－ 324. DOI: 10.1245/s10434－012－2312－8.
[22]	LE ROY B, GELLI M, PITTAU G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105( 7): 839－ 847. DOI: 10.1002/bjs.10641.
[23]	CSCO Committee of Experts on Biliary Tumors. Expert consensus on diagnosis and treatment of CSCO biliary systerm tumors(2019 edition)[J]. Chin Clin Oncol, 2019, 24( 9): 828－ 838. DOI: 10.3969/j.issn.1009－0460.2019.09.014. 胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24( 9): 828－ 838. DOI: 10.3969/j.issn.1009－0460.2019.09.014.
[24]	JIANG JH, FANG DZ, HU YT. Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: A systematic review and meta－analysis[J]. BMJ Open, 2023, 13( 5): e067222. DOI: 10.1136/bmjopen－2022－067222.
[25]	MAVROS MN, ECONOMOPOULOS KP, ALEXIOU VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta－analysis[J]. JAMA Surg, 2014, 149( 6): 565－ 574. DOI: 10.1001/jamasurg.2013.5137.
[26]	LIN KY, LIN ZW, CHEN QJ, et al. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti－PD－1 antibody: A retrospective multicenter study of 83 patients[J]. Hepatol Int, 2023. DOI: 10.1007/s12072－023－10561－6.
[27]	MARRON TU, FIEL MI, HAMON P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single－arm, open－label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7( 3): 219－ 229. DOI: 10.1016/S2468－1253(21)00385－X.
[28]	XIA YX, TANG WW, QIAN XF, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: A single－arm, open label, phase II clinical trial[J]. J Immunother Cancer, 2022, 10( 4): e004656. DOI: 10.1136/jitc－2022－004656.
[29]	KASEB AO, HASANOV E, CAO HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open－label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7( 3): 208－ 218. DOI: 10.1016/S2468－1253(21)00427－1.
[30]	YANG Y, LIN KY, LIU L, et al. Impact of preoperative TACE on incidences of microvascular invasion and long－term post－hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis[J]. Cancer Med, 2021, 10( 6): 2100－ 2111. DOI: 10.1002/cam4.3814.
[31]	LI N, FENG S, XUE J, et al. Hepatocellular carcinoma with main portal vein tumor thrombus: A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB, 2016, 18( 6): 549－ 556. DOI: 10.1016/j.hpb.2016.04.003.
[32]	WEI XB, JIANG YB, ZHANG XP, et al. Neoadjuvant three－dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor Thrombus: A randomized, open－label, multicenter controlled study[J]. J Clin Oncol, 2019, 37( 24): 2141－ 2151. DOI: 10.1200/JCO.18.02184.
[33]	ZHAO HT, CAI JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma[J]. World J Gastroenterol, 2021, 27( 47): 8069－ 8080. DOI: 10.3748/wjg.v27.i47.8069.
[34]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362( 14): 1273－ 1281. DOI: 10.1056/NEJMoa0908721.
[35]	ANDRÉ T, REYES－VIDAL JM, FARTOUX L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study[J]. Br J Cancer, 2008, 99( 6): 862－ 867. DOI: 10.1038/sj.bjc.6604628.
[36]	MORIZANE C, OKUSAKA T, MIZUSAWA J, et al. Combination gemcitabine plus S－1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA－BT(JCOG1113) randomized phase III clinical trial[J]. Ann Oncol, 2019, 30( 12): 1950－ 1958. DOI: 10.1093/annonc/mdz402.
[37]	SAHAI V, CATALANO PJ, ZALUPSKI MM, et al. Nab－paclitaxel and gemcitabine as first－line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2018, 4( 12): 1707－ 1712. DOI: 10.1001/jamaoncol.2018.3277.
[38]	SHROFF RT, JAVLE MM, XIAO LC, et al. Gemcitabine, cisplatin, and nab－paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5( 6): 824－ 830. DOI: 10.1001/jamaoncol.2019.0270.
[39]	UTUAMA O, PERMUTH JB, DAGNE G, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: A propensity score survival analysis supporting use in patients with high－risk disease[J]. Ann Surg Oncol, 2021, 28( 4): 1939－ 1949. DOI: 10.1245/s10434－020－09478－3.
[40]	FRUSCIONE M, PICKENS RC, BAKER EH, et al. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review[J]. Curr Probl Cancer, 2021, 45( 1): 100614. DOI: 10.1016/j.currproblcancer.2020.100614.
[41]	KAMARAJAH S, GIOVINAZZO F, ROBERTS KJ, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis[J]. Ann Hepatobiliary Pancreat Surg, 2020, 24( 1): 6－ 16. DOI: 10.14701/ahbps.2020.24.1.6.
[42]	RIBY D, MAZZOTTA AD, BERGEAT D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27( 10): 3729－ 3737. DOI: 10.1245/s10434－020－08486－7.
[43]	TAO RD, KRISHNAN S, BHOSALE PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis[J]. J Clin Oncol, 2016, 34( 3): 219－ 226. DOI: 10.1200/JCO.2015.61.3778.
[44]	HONG TS, WO JY, YEAP BY, et al. Multi－institutional phase II study of high－dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34( 5): 460－ 468. DOI: 10.1200/JCO.2015.64.2710.
[45]	IBRAHIM SM, MULCAHY MF, LEWANDOWSKI RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium－90 microspheres: Results from a pilot study[J]. Cancer, 2008, 113( 8): 2119－ 2128. DOI: 10.1002/cncr.23818.
[46]	MOULI S, MEMON K, BAKER T, et al. Yttrium－90 radioembolization for intrahepatic cholangiocarcinoma: Safety, response, and survival analysis[J]. J Vasc Interv Radiol, 2013, 24( 8): 1227－ 1234. DOI: 10.1016/j.jvir.2013.02.031.
[47]	AL－ADRA DP, GILL RS, AXFORD SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium－90 radioembolization: A systematic review and pooled analysis[J]. Eur J Surg Oncol, 2015, 41( 1): 120－ 127. DOI: 10.1016/j.ejso.2014.09.007.
[48]	CUCCHETTI A, CAPPELLI A, MOSCONI C, et al. Improving patient selection for selective internal radiation therapy of intra－hepatic cholangiocarcinoma: A meta－regression study[J]. Liver Int, 2017, 37( 7): 1056－ 1064. DOI: 10.1111/liv.13382.
[49]	SHROFF RT, KENNEDY EB, BACHINI M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37( 12): 1015－ 1027. DOI: 10.1200/JCO.18.02178.
[50]	KE Q, LIN NP, DENG MJ, et al. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta－analysis[J]. PLoS One, 2020, 15( 2): e0229292. DOI: 10.1371/journal.pone.0229292.
[51]	BURGER I, HONG K, SCHULICK R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution[J]. J Vasc Interv Radiol, 2005, 16( 3): 353－ 361. DOI: 10.1097/01.RVI.0000143768.60751.78.
[52]	HERBER S, OTTO G, SCHNEIDER J, et al. Transarterial chemoembolization(TACE) for inoperable intrahepatic cholangiocarcinoma[J]. Cardiovasc Intervent Radiol, 2007, 30( 6): 1156－ 1165. DOI: 10.1007/s00270－007－9032－7.
[53]	HYDER O, MARSH JW, SALEM R, et al. Intra－arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi－institutional analysis[J]. Ann Surg Oncol, 2013, 20( 12): 3779－ 3786. DOI: 10.1245/s10434－013－3127－y.
[54]	LE VH, O’CONNOR VV, LI DN, et al. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate[J]. J Surg Oncol, 2021, 123( 1): 164－ 171. DOI: 10.1002/jso.26230.
[55]	CAI Z, HE C, ZHAO C, et al. Survival comparisons of hepatic arterial infusion chemotherapy with mFOLFOX and transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma[J]. Front Oncol, 2021, 11: 611118. DOI: 10.3389/fonc.2021.611118.
[56]	JARNAGIN WR, SCHWARTZ LH, GULTEKIN DH, et al. Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE－MRI as a biomarker of survival[J]. Ann Oncol, 2009, 20( 9): 1589－ 1595. DOI: 10.1093/annonc/mdp029.
[57]	KEMENY NE, SCHWARTZ L, GÖNEN M, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results?[J]. Oncology, 2011, 80( 3－ 4): 153－ 159. DOI: 10.1159/000324704.
[58]	KONSTANTINIDIS IT, GROOT KOERKAMP B, DO RKG, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122( 5): 758－ 765. DOI: 10.1002/cncr.29824.
[59]	CERCEK A, BOERNER T, TAN BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2020, 6( 1): 60－ 67. DOI: 10.1001/jamaoncol.2019.3718.
[60]	RIZZO A, RICCI AD, BRANDI G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?[J]. Cancer Treat Res Commun, 2021, 27: 100356. DOI: 10.1016/j.ctarc.2021.100356.
[61]	MA BQ, MENG HJ, TIAN Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma[J]. BMC Cancer, 2020, 20( 1): 318. DOI: 10.1186/s12885－020－06804－6.
[62]	LOWERY MA, BURRIS HA 3, JANKU F, et al. Safety and activity of ivosidenib in patients with IDH1－mutant advanced cholangiocarcinoma: A phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4( 9): 711－ 720. DOI: 10.1016/S2468－1253(19)30189－X.
[63]	AITCHESON G, MAHIPAL A, JOHN BV. Targeting FGFR in intrahepatic cholangiocarcinoma[iCCA]: Leading the way for precision medicine in biliary tract cancer[BTC][J]. Expert Opin Investig Drugs, 2021, 30( 4): 463－ 477. DOI: 10.1080/13543784.2021.1900821.
[64]	ABOU－ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open－label, phase 2 study[J]. Lancet Oncol, 2020, 21( 5): 671－ 684. DOI: 10.1016/S1470－2045(20)30109－1.
[65]	FISTE O, NTANASIS－STATHOPOULOS I, GAVRIATOPOULOU M, et al. The emerging role of immunotherapy in intrahepatic cholangiocarcinoma[J]. Vaccines, 2021, 9( 5): 422. DOI: 10.3390/vaccines9050422.
[66]	FANG C, XIA Y, WANG K, et al. Conversion therapy for intrahepatic cholangiocarcinoma: Status and perspectives[J]. J Surg Concepts Pract, 2022, 27( 2): 107－ 112. DOI: 10.16139/j.1007－9610.2022.02.004. 方诚, 夏勇, 王葵, 等. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27( 2): 107－ 112. DOI: 10.16139/j.1007－9610.2022.02.004.
[67]	FENG KC, LIU Y, ZHAO YT, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase II study[J]. J Immunother Cancer, 2020, 8( 1): e000367. DOI: 10.1136/jitc－2019－000367.
[68]	ZHANG QY, LIU XY, WEI SM, et al. Lenvatinib plus PD－1 inhibitors as first－line treatment in patients with unresectable biliary tract cancer: A single－arm, open－label, phase II study[J]. Front Oncol, 2021, 11: 751391. DOI: 10.3389/fonc.2021.751391.
[69]	ZHU SG, LI HB, DAI TX, et al. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD－1 inhibitor camrelizumab: A case report[J]. World J Clin Cases, 2022, 10( 27): 9743－ 9749. DOI: 10.12998/wjcc.v10.i27.9743.
[70]	ZHANG Z, ZHANG WW, WANG HG, et al. Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD－L1 expression by PD－1 blockade combined with tyrosine kinase inhibitors: A case report[J]. Front Immunol, 2021, 12: 744571. DOI: 10.3389/fimmu.2021.744571.
[71]	CANTRELL CK, WHITE J. Successful management of an“unresectable” intrahepatic cholangiocarcinoma with neoadjuvant systemic therapy, chemoembolization, and extended hepatectomy with portal vein reconstruction[J]. Cureus, 2018, 10( 5): e2696. DOI: 10.7759/cureus.2696.